James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. FWBI recently shared insights on Benzinga’s All-Access.
First Wave BioPharma is dedicated to pioneering non-systemic therapies for gastrointestinal (GI) diseases. The company is pursuing research on numerous revolutionary therapies for GI diseases.
You can watch the full interview here.
Featured photo by Hans Reniers on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
